In this regard, ADCs used in breast cancer treatment include Kadcyla and Enhertu, targeting human epidermal growth factor receptor 2 (HER2) [2], and Trodelvy, targeting trophoblast cell surface antigen-2 (TROP2) [3]. This evidence concerns the gene TACSTD2 and breast carcinoma.